DuPont de Nemours, Inc. (DD) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is balanced-to-slightly-positive — consensus sits modestly above guidance midpoints, but management's raised full-year guide and strong April order trends suggest the bar is achievable; the single biggest swing factor is whether Middle East logistics disruptions in Water have fully normalized or linger into Q2.

Heading into Q2 2026, DuPont's consensus estimate of ~$1.81B in revenue and ~$432M in Operating EBITDA sits just above the company's own guidance of ~$1.80B and ~$430M, leaving a thin but not punishing cushion. Management's tone has been notably more confident since the Q1 print — the full-year guide was raised on both top line and EPS, a $275M accelerated share repurchase was launched, and April order trends were described as tracking well year-over-year. Estimate revisions have been broadly stable-to-slightly-up since the Q1 beat, suggesting the Street has largely absorbed the guidance raise without building in incremental upside. The stock has underperformed the S&P 500 by roughly 9 points since the Q1 print (DD indexed ~95.6 vs. SPY ~104.7 as of August 4), despite the beat-and-raise, implying the market is not pricing in a repeat outperformance — a setup that could reward a clean Q2 delivery. The key wildcard is Water: management guided mid-single-digit organic growth for Q2 in Healthcare & Water, predicated on the ~$10M of Middle East-delayed shipments having cleared in April; any re-emergence of logistics disruptions or project-timing slippage in large desalination contracts would be the most likely source of a negative surprise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sits modestly above guidance midpoints on both revenue and EBITDA, making the bar achievable but not easy. Operating EBITDA margin is the bigger swing factor — Q1 delivered 230bps of YoY expansion and the Street is pricing in continued momentum; any mix or productivity shortfall would be the most visible miss.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data. Q2 2026 guidance from Q1 2026 earnings call (May 5, 2026). Note: DD completed a 1-for-3 reverse stock split on June 24, 2026; all EPS figures above are on the post-split basis. Prior year Q2 2025 EPS of $1.12 (pre-split) equates to ~$0.37 on a post-split comparable basis. Consensus EPS of $0.58 reflects post-split adjusted figures.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI #1: Total Revenue

Top KPI #2: Operating EBITDA

Pattern: Comparable beat/miss history is limited to Q4 2025 and Q1 2026 given the Qnity Electronics separation completed in late 2025, which reset the standalone DD consensus series. In both available quarters, DD beat Operating EBITDA consensus by a meaningful margin (+6.2% and +5.6%), suggesting management has been guiding conservatively. Revenue beats have been narrower (+0.3% and +1.0%), consistent with a company that guides revenue tightly and beats on margin. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not been formally revised since the Q1 2026 earnings call, but management's tone has been constructive — April order trends were described as tracking well, and the full-year guide was already raised at Q1. No post-earnings 8-K or conference update has changed the Q2 or FY2026 numbers.

Tone shift since Q1: Management's posture has been constructive. On the Q1 call, CEO Lori Koch noted April order trends were "very similar demand as we have been seeing and nice increases overall on a year-over-year basis." The company also launched an additional $275M ASR immediately post-Q1, signaling confidence in cash generation. No guidance revisions have been issued via 8-K or conference since May 5, 2026. The key segment-level tone: Healthcare expected to land mid-to-high single digits for the full year; Water expected to be about flat in H1 and up in H2; Construction expected to be about flat for the full year with ~1% price contribution.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since the Q1 print, tracking guidance closely on EBITDA and EPS. The modest gap between FY2026 revenue consensus ($7.02B) and guidance midpoint ($7.19B) is the most notable divergence — the Street appears to be discounting H2 construction and Water recovery assumptions, which represents a potential source of upside if management's targets prove achievable.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of 5/12/2026 (5 trading days post Q1 2026 earnings). Estimates have been remarkably stable since the Q1 print, with virtually no revision in either direction across all KPIs. The primary divergence is FY2026 revenue, where the Street sits ~$167M below management's midpoint — likely reflecting skepticism on H2 Water project timing and construction recovery. EBITDA and EPS consensus are essentially at guidance midpoints, suggesting the market trusts the margin story but is more cautious on top-line recovery.

5. Stock Performance

Key Takeaway: DD has underperformed both the S&P 500 and the XLB Materials ETF since the Q1 2026 earnings print, despite a beat-and-raise quarter — suggesting multiple compression rather than earnings-driven weakness. The stock is down ~4.4% since May 5 vs. SPY +4.7%, a ~9-point gap that likely reflects lingering perception as a chemical company rather than a re-rated multi-industrial.

DD vs. XLB (Materials ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 5, 2026). Source: Yahoo Finance / Stock Price Data.

• DD (dark navy): Indexed to 95.6 as of August 4, 2026 — down ~4.4% since Q1 earnings.
• XLB Materials ETF (grey dashed): Indexed to 99.0 — down ~1.0%, outperforming DD by ~3.4 points.
• S&P 500 / SPY (light grey dashed): Indexed to 104.7 — up ~4.7%, outperforming DD by ~9.1 points.
• Key event: 1-for-3 reverse stock split completed June 24, 2026 (annotated on chart). This was a cosmetic change with no economic impact on shareholders.
• Interpretation: The underperformance is notable given the Q1 beat-and-raise. The stock's muted reaction on Q1 earnings day (per the summary knowledge) and subsequent drift lower suggest the market is waiting for evidence of sustained execution rather than re-rating on guidance alone. A clean Q2 print with Water recovery confirmation could be the catalyst for multiple re-rating toward multi-industrial peers.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the 1-for-3 reverse stock split completed June 24, 2026, which reduces share count optics and may support GICS reclassification efforts. No material guidance changes or M&A announcements have been made since the Q1 print.

• June 24, 2026 — 1-for-3 Reverse Stock Split Completed (8-K): DuPont completed a 1-for-3 reverse stock split, reducing shares outstanding by two-thirds and tripling the per-share price. Approved by shareholders on May 21, 2026 and by the Board on May 26, 2026. New CUSIP: 26614N 201. Stock continues to trade on NYSE under "DD." Implication: Cosmetic change with no economic impact; may be part of the company's effort to achieve GICS multi-industrial reclassification by aligning share price optics with industrial peers.
• July 14, 2026 — Q2 2026 Earnings Scheduled (Press Release): DuPont confirmed Q2 2026 results will be released at 6:00 a.m. ET on August 4, 2026, followed by a conference call at 8:00 a.m. ET. No pre-announcement or guidance update was included. Implication: Absence of a pre-announcement is a mild positive signal — management did not feel compelled to warn on Q2 results.
• May 5, 2026 — Q1 2026 Beat-and-Raise + $275M ASR Launch: DuPont reported Q1 2026 results above guidance on all metrics. Full-year 2026 guidance raised: net sales to ~$7.185B (+$80M), Operating EBITDA to ~$1.745B, Adj. EPS to $2.35–$2.40 (+$0.10). Simultaneously launched a $275M accelerated share repurchase (on top of the previously completed $500M ASR), funded by Aramids divestiture proceeds. Implication: Sets a higher bar for Q2 but demonstrates management confidence in cash generation and capital return capacity.
• April 1, 2026 — Aramids Divestiture Closed: DuPont completed the sale of its Aramids business, generating ~$1.2B gross / ~$1.1B net proceeds. Proceeds are being deployed into the ASR program and held for potential M&A. Implication: Portfolio simplification continues; management has flagged medical packaging and CDMO (Spectrum) as M&A targets. Watch for any deal announcement alongside Q2 results.
• Ongoing — Middle East Conflict / Water Logistics: ~$10M of Water segment sales were delayed in Q1 due to Middle East logistics disruptions; management confirmed these shipped in April. Total Middle East exposure is ~$300M (~4% of revenue), split evenly between sales into and sourcing from the region. Large H2 desalination projects remain on track per Q1 commentary. Implication: Key watch item for Q2 — any re-emergence of disruption would be the primary downside risk to Water segment guidance.
• Ongoing — Analyst Ratings Activity: Post-Q1, multiple banks raised price targets: RBC raised to $180 (from $168) on May 7; Deutsche Bank raised to $180 (from $174) on May 7; UBS raised to $177 (from $168) on May 5. Goldman Sachs initiated coverage at Neutral with a $159 PT on June 15. Consensus rating is Moderate Buy (12 Buy, 3 Hold, 1 Sell out of 17 analysts). Average PT ~$55 on a post-split basis (~$165 pre-split equivalent). Implication: Broad buy-side support but Goldman's Neutral initiation at a below-consensus PT introduces a notable skeptical voice.
• Ongoing — 80/20 Strategy & Operational Excellence: Four Diversified Industrials businesses selected for 80/20 process; ~2/3 of initial study completed as of Q1. New Danaher executive hire leading enhanced lean framework. No top-line or margin impact baked into FY2026 guide from implementation. Implication: Medium-term margin catalyst; any update on implementation progress or early results would be a positive signal.

7. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peers reporting Q2 2026 results in late July paint a broadly constructive but mixed picture for DD's key end markets. Healthcare/biopharma demand is accelerating (Ecolab Life Sciences +15%, Avantor pharma/biotech improving), aerospace remains strong (PPG double-digit, Linde >1/3 of manufacturing growth), and water/microelectronics is robust (Ecolab Global High Tech +29%). The key risk read-through is construction — Sherwin-Williams sees no broad demand recovery and SHW/Axalta both flag North America industrial/construction as still weak. Middle East disruptions continue to weigh on peers (Ecolab -1% volume headwind, Linde helium supply disruption), consistent with DD's own exposure.

Note: All peer commentary below is from Q2 2026 earnings calls (reported July 28–31, 2026), covering the same calendar quarter as DD's upcoming Q2 2026 report. These are current-quarter read-throughs, not prior-quarter results.

Ecolab (ECL) — Q2 2026 Earnings (July 28, 2026)

Relevance to DD: ECL is a direct read-through on DD's Water and Healthcare/Biopharma end markets.

• Life Sciences (Biopharma/Healthcare) accelerated to +15% growth in Q2, driven by very strong share gains in bioprocessing and pharma/personal care. "In bioprocessing, we continue to take market share with the innovative technologies we've launched over the last few years. As a result, our business continues to rapidly scale as customers move their drugs into commercial manufacturing." DD read-through: Strongly positive for DD's Liveo (biopharma/CDMO) and Spectrum businesses, which saw strong Q1 recovery. Biopharma demand appears to be a durable trend, not a one-quarter bounce.
• Global High Tech (Water/Microelectronics) accelerated to +29% growth, driven by "very strong demand across both microelectronics and data centers, driven by the rapid build-out of AI infrastructure." ECL raised its Global High Tech growth target to >25% annually, reaching $4B in sales by 2030. DD read-through: Positive for DD's Water segment microelectronics exposure (~20% of ion exchange). AI/data center-driven water demand is accelerating, which supports DD's H2 Water recovery thesis.
• Middle East disruption caused a nearly 1% headwind to ECL volumes in Q2, with ongoing disruption expected in H2. "Volumes are expected to continue to grow as strong new business wins more than offset ongoing disruption in the Middle East." DD read-through: Confirms Middle East logistics disruptions are real and ongoing for water-exposed companies. DD's claim that the $10M Q1 delay shipped in April is plausible, but ECL's commentary suggests the broader disruption environment has not fully normalized.
• Pricing strengthened to 4% in Q2, with H2 expected at 5–6% as energy surcharge benefits are fully realized. DD read-through: Supports DD's pricing actions (~$90M incremental cost coverage, ~$25M Q2 price on top line). The pricing environment for specialty chemical/water companies appears supportive.

Sherwin-Williams (SHW) — Q2 2026 Earnings (July 28, 2026)

Relevance to DD: SHW is the most direct read-through on DD's Construction/Shelter end market (~25% of DD revenue).

• No broad-based demand recovery in construction: "Our updated outlook assumes there is not a broad based demand recovery. Customer feedback and the leading indicators we track continue to show limited signs of meaningful improvement in most end markets." New residential "remained very challenging as single family starts and completions have been negative for five of the last six months." DD read-through: Negative for DD's Building Technologies (construction) sub-segment. DD guided construction to be "about flat" for FY2026 with ~1% price contribution; SHW's commentary suggests the underlying market remains weak, making flat organic growth dependent on pricing rather than volume recovery.
• Raw material inflation accelerating: SHW expects raw material basket inflation "up in the high single digit range in the second half," moving full-year outlook to mid-single digits. Announced an 8% price increase effective September 1. DD read-through: Consistent with DD's own Middle East-driven input cost inflation (~$90M incremental costs). Confirms the pricing environment is supportive for DD's surcharge/price actions.
• Commercial and Protective & Marine remain strong: Commercial sales up high single digits; Protective & Marine up mid-teens for the 8th consecutive quarter of at least high single-digit growth, driven by data centers, semiconductor infrastructure, and manufacturing onshoring. DD read-through: Positive for DD's Industrial Technologies (aerospace, automotive) sub-segment. Data center and infrastructure demand is a tailwind for DD's construction-adjacent industrial businesses.

Linde (LIN) — Q2 2026 Earnings (July 31, 2026)

Relevance to DD: LIN provides read-throughs on aerospace, electronics/semiconductor, and industrial end markets.

• Electronics is the fastest-growing end market, with +18% YoY growth in Q2, driven by project start-ups and "higher demand tied to hardware associated with AI." LIN added $1B of new electronics wins to its backlog. DD read-through: Positive for DD's Water microelectronics exposure and any semiconductor-adjacent materials. AI infrastructure build-out is a durable demand driver.
• Aerospace accounted for more than a third of manufacturing growth in Q2, with momentum expected to carry into H2. DD read-through: Positive for DD's Industrial Technologies aerospace sub-segment, which was a key driver of Diversified Industrials organic growth in Q1.
• Middle East helium supply disruption ongoing: LIN navigated complex supply chain issues but noted "normalization of the helium market is not expected this year." Countries in Asia highly dependent on Middle East hydrocarbons have "had to scale back industrial activity." DD read-through: Confirms Middle East disruptions are broader than just DD's water logistics. The industrial activity slowdown in Asia could be a modest headwind for DD's Diversified Industrials segment.
• No economic improvement assumed at guidance midpoint for H2: "The range assumes no economic improvement at the midpoint." Base volumes showed some recovery in Q2 but LIN wants "a few more quarters under our belt before incorporating this trend into future guides." DD read-through: Neutral — suggests industrial peers are being cautious on H2 macro assumptions, consistent with DD's own conservative construction/shelter outlook.

Avantor (AVTR) — Q2 2026 Earnings (July 29, 2026)

Relevance to DD: AVTR is a direct read-through on DD's biopharma/CDMO (Spectrum/Liveo) end markets.

• Pharma and biotech customer activity provided a tailwind in Q2, "especially in the USA and America. Funding is returning to biotech, leading to increased spending, which includes a mix of equipment and consumables." AVTR's VW (distribution) segment returned to positive organic growth (+1.7%) earlier than anticipated. DD read-through: Positive for DD's Liveo (biopharma) and Spectrum (CDMO) businesses. Biotech funding recovery and increased pharma spending are consistent with DD's Q1 commentary on strong Liveo demand recovery.
• BNP (Bioscience/MedTech Products) segment declined 5.6% organically in Q2, but delivered double-digit order growth and a book-to-bill of 1.1. "BNP delivered double-digit order growth and a book-to-bill ratio of 1.1 during Q2. Order trends were healthy across all business units." DD read-through: Mixed — near-term revenue headwinds from discrete factors, but strong order book suggests underlying demand is healthy. DD's medical device/packaging exposure (Tyvek, Spectrum) should benefit from the same underlying demand trends.
• Company raised 2026 organic revenue growth guidance and is "confident and optimistic that 2027 will be a growth year" despite near-term headwinds. DD read-through: Positive tone on biopharma/life sciences end market trajectory, supporting DD's mid-to-high single-digit Healthcare growth target for FY2026.

PPG Industries (PPG) — Q2 2026 Earnings (July 29, 2026)

Relevance to DD: PPG provides read-throughs on aerospace, automotive, packaging, and construction end markets.

• Aerospace achieved double-digit percentage growth with order backlog remaining ~$300M. PPG is investing >$500M in additional aerospace capacity. "Demand is expected to remain robust given our highly specialized and qualified products for both the OEM and aftermarket channels." DD read-through: Strongly positive for DD's aerospace exposure within Industrial Technologies. Aerospace demand appears durable and broad-based across multiple peers.
• Architectural coatings (construction) organic growth was only +2% in Q2, driven by price rather than volume. New residential "remained very challenging." PPG expects flat to low single-digit organic growth in Q3 for architectural. DD read-through: Consistent with DD's own construction weakness narrative. Confirms that construction market recovery is price-driven, not volume-driven — supportive of DD's ~1% price contribution assumption for construction.
• Packaging coatings grew double-digits for the third consecutive quarter, with volumes up >20% on a two-year stacked basis. DD read-through: Positive for DD's printing and packaging businesses within Diversified Industrials, which management guided to normalize to low single-digit growth for FY2026 after Q1 weakness.
• Middle East (Iraq war) driving raw material, energy, logistics, and packaging cost inflation: PPG covered ~90% of COGS inflation with pricing in Q2, targeting 100% by Q4. "We have proactively made price adjustments globally and across all of our businesses, resulting in a net 2% selling price improvement in the quarter." DD read-through: Confirms the pricing environment is supportive for DD's surcharge/price actions. DD's ~$90M incremental cost coverage plan appears achievable given peer execution.

Axalta Coating Systems (AXTA) — Q2 2026 Earnings (July 28, 2026)

Relevance to DD: AXTA provides read-throughs on automotive and industrial coatings end markets.

• Industrial segment delivered best margins in Axalta's history in Q2, despite North America remaining "choppy and challenged." "North America still remains choppy and challenged... it's really tied to consumer confidence and interest rates and house building." DD read-through: Consistent with DD's construction weakness narrative. North America residential construction remains a headwind for building-products-exposed businesses.
• Automotive refinish destocking is "mostly complete" in Q2 and Q3, with volumes expected to be slightly up in H2. Commercial vehicle net sales up +7% YoY. DD read-through: Positive for DD's automotive exposure within Industrial Technologies. Automotive demand appears to be stabilizing/recovering, consistent with DD's Q1 commentary on automotive strength.
• Raw material headwind of low single digits in Q2, expected to tick up to high single digits by year-end. Solvents up ~15–20% due to oil prices; monomers up high single digits. DD read-through: Confirms raw material inflation is real and accelerating. DD's pricing actions to cover ~$90M of incremental Middle East-related costs appear well-timed.

Eastman Chemical (EMN) — Q2 2026 Earnings (July 31, 2026)

Relevance to DD: EMN provides read-throughs on specialty chemicals demand, pharma/water, and industrial end markets.

• Economy described as "incredibly weak right now" with brands struggling on both consumer durables and consumer packaging. However, "stable markets" (pharma, water treatment, ag, personal care, aviation) represent two-thirds of AFP revenue and are showing "solid, moderate growth." DD read-through: Mixed — weak macro for discretionary/consumer end markets, but stable/growing for DD's core Healthcare and Water markets. DD's portfolio skew toward secular growth markets (Healthcare, Water) is a relative advantage in this environment.
• Ultra-high purity solvents for semiconductors "growing at very high rates with the market, at good margins". AFP segment showing resilient margins despite challenging end markets. DD read-through: Positive for DD's Water microelectronics and semiconductor-adjacent materials exposure.
• July orders "holding up well and on track" vs. Q2, with no significant customer destocking observed. "We don't think that people are sitting on significant inventories right now." DD read-through: Positive signal for Q2 demand trends. Absence of destocking is consistent with DD's April order commentary ("very similar demand as we have been seeing and nice increases overall on a year-over-year basis").

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by insiders since the Q1 earnings print. All transactions are either routine equity award grants (code A) or tax-withholding share forfeitures (code F) associated with vesting events — nothing that signals directional conviction from management or the board.

* Directors receiving annual equity grants (May 21, 2026): Brady Amy G., Breen Edward D., Chandy Ruby R., Cutler Alexander M., du Pont Eleuthere I., Lico James A., Lowery Frederick M., Macpherson Donald G., McMaken Kurt B. Additional grants to Cutler and others on May 29 / June 2 reflect quarterly director compensation cycles.

Source: SEC Form 4 Filings Database (Insider Transaction Data). All transactions are code A (equity award/grant) or code F (tax withholding on vesting) — neither constitutes an open-market buy or discretionary sale. No Form 4 code P (open-market purchase) or code S (open-market sale) transactions were filed by DD insiders in the period since Q1 2026 earnings (May 5, 2026 through August 3, 2026). The absence of open-market activity is neutral — neither a bullish nor bearish signal.

Note on share counts: All share figures above are on a pre-split basis (prior to the June 24, 2026 1-for-3 reverse stock split). Post-split equivalent share counts would be approximately one-third of the figures shown.